These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25755880)
1. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Abell SK; Teng J; Dowling A; Hofman MS; MacIsaac RJ; Sachithanandan N Endocrinol Diabetes Metab Case Rep; 2015; 2015():140097. PubMed ID: 25755880 [TBL] [Abstract][Full Text] [Related]
2. The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma. North AS; Thakkar RG; James RA; Hammond JS Ann R Coll Surg Engl; 2022 Jun; 104(6):e180-e182. PubMed ID: 35133207 [TBL] [Abstract][Full Text] [Related]
3. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448 [TBL] [Abstract][Full Text] [Related]
5. Clinical Profile and Efficacy of Long-Acting Octreotide in Hyperinsulinemic Hypoglycaemia. Kubsad PS; Vani HN; Sheshadri T; Palany R Indian J Endocrinol Metab; 2024; 28(3):289-294. PubMed ID: 39086574 [TBL] [Abstract][Full Text] [Related]
6. Management of refractory hypoglycaemia in a metastatic neuroendocrine tumour co-secreting serotonin and insulin. Bhullar JS; Leung JM; Almehthel MS BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33168531 [TBL] [Abstract][Full Text] [Related]
7. Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. Kyriacou A; Mansoor W; Lawrance J; Trainer PJ Hormones (Athens); 2016; 15(1):118-21. PubMed ID: 26188238 [TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893 [TBL] [Abstract][Full Text] [Related]
9. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Gama R; Marks V; Wright J; Teale JD Clin Endocrinol (Oxf); 1995 Jul; 43(1):117-20; discussion 120-2. PubMed ID: 7641403 [TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours. Alsadik S; Yusuf S; Al-Nahhas A Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538 [TBL] [Abstract][Full Text] [Related]
11. Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours. Wiesli P; Pavlicek V; Brändle M; Pfammatter T; Perren A; Schmid C Endocrinol Diabetes Metab; 2019 Oct; 2(4):e00083. PubMed ID: 31592116 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Öberg K; Lamberts SW Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899 [TBL] [Abstract][Full Text] [Related]
13. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report. Alberts AS; Falkson G S Afr Med J; 1988 Jul; 74(2):75-6. PubMed ID: 2899913 [TBL] [Abstract][Full Text] [Related]
14. A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma. Sandoval MA; Pagsisihan D; Berberabe A; Palugod-Lopez EG BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26994053 [TBL] [Abstract][Full Text] [Related]
15. A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Kitade H; Ohtsubo K; Hokkoku K; Mori M; Osamura RY; Sakuma H; Nakai M; Yano S Int Cancer Conf J; 2019 Jan; 8(1):24-28. PubMed ID: 31149542 [TBL] [Abstract][Full Text] [Related]
16. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Ong GS; Henley DE; Hurley D; Turner JH; Claringbold PG; Fegan PG Eur J Endocrinol; 2010 May; 162(5):1001-8. PubMed ID: 20164213 [TBL] [Abstract][Full Text] [Related]
17. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620 [TBL] [Abstract][Full Text] [Related]
18. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
19. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours. Costa F; Gumz B Eur Endocrinol; 2014 Feb; 10(1):70-74. PubMed ID: 29872467 [TBL] [Abstract][Full Text] [Related]
20. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia. Cotterill AM; Holly JM; Amiel S; Wass JA Clin Endocrinol (Oxf); 1993 Jun; 38(6):633-9. PubMed ID: 7687525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]